MUC16 in ovarian cancer: high, stable expression across histologic subtypes, disease stages, and platinum sensitivity status supports antibody-drug conjugate development

Whitehawk Therapeutics Inc. published this content on April 12, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 12, 2026 at 16:22 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]